NCT00606034View on ClinicalTrials.gov

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Type 2 DiabetesInsulin Resistance
Interventions
DRUG

U-500 Insulin delivered by Omnipod (disposable insulin pump)

U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs

Trial Locations (1)

28803

Mountain Diabetes and Endocrine Center, Asheville

All Listed Sponsors
lead

Mountain Diabetes and Endocrine Center

OTHER

NCT00606034 - U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod | Biotech Hunter | Biotech Hunter